Journal of the American Heart Association, Volume 15, Issue 6 , March 17, 2026. BackgroundHeart failure with preserved ejection fraction (HFpEF) is characterized by chronic low‐grade inflammation, which influences endothelial function, affecting glycocalyx integrity, barrier permeability, and cell adhesion.
The role of endothelial glycocalyx shedding in the onset and progression of HFpEF remains poorly understood. Our aim was to investigate the association of glycocalyx degradation biomarkers, hyaluronan and syndecan‐1, with patient characteristics and clinical outcomes in HFpEF and at population level.MethodsCirculating hyaluronan and syndecan‐1 concentrations were assessed in a population‐based cohort (STANISLAS [Suivi Temporaire Annuel Non‐Invasif de la Santé des Lorrains Assurés Sociaux], n=959) and a cohort with HFpEF (NETDiamond [New Targets in Diastolic Heart Failure: From Comorbidities to Personalized Medicine], n=86).ResultsHyaluronan levels increased with age in both the population cohort and the cohort with HFpEF.
Journal of the American Heart Association published a clinical update in Cardiology on 13 Mar 2026.
The item focuses on Hyaluronan and Syndecan‐1: Linking Glycocalyx Degradation to Development and Progression of Heart Failure With Preserved Ejection Fraction.
Review the original article for the full source wording and details.